Report Detail
EMEA (Europe, Middle East and Africa) Renal Cell Cacinoma Drugs Market Report 2018
- RnM1775869 |
- 4 June, 2018 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
In this report, the EMEA Renal Cell Cacinoma Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Renal Cell Cacinoma Drugs for these regions, from 2013 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Renal Cell Cacinoma Drugs market competition by top manufacturers/players, with Renal Cell Cacinoma Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
F. Hoffmann-La Roche Ag
Genentech, Inc.
Glaxosmithkline Plc
Novartis Ag
Onyx
Pfizer, Inc.
On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hospital
Clinic
Other
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Renal Cell Cacinoma Drugs Market Report 2018
1 Renal Cell Cacinoma Drugs Overview
- 1.1 Product Overview and Scope of Renal Cell Cacinoma Drugs
- 1.2 Classification of Renal Cell Cacinoma Drugs
- 1.2.1 EMEA Renal Cell Cacinoma Drugs Market Size (Sales) Comparison by Type (2013-2025)
- 1.2.2 EMEA Renal Cell Cacinoma Drugs Market Size (Sales) Market Share by Type (Product Category) in 2017
- 1.2.3 Afinitor (Everolimus)
- 1.2.4 Avastin (Bevacizumab)
- 1.2.5 Cabomety (Cabozantinib)
- 1.2.6 Inlyta (Axitinib)
- 1.2.7 Nexavar (Sorafenib)
- 1.2.8 Proleukin (Aldesleukin)
- 1.2.9 Torisel (Temsirolimus)
- 1.2.10 Sutent (Sunitinib)
- 1.2.11 Votrient (Pazopanib)
- 1.3 EMEA Renal Cell Cacinoma Drugs Market by Application/End Users
- 1.3.1 EMEA Renal Cell Cacinoma Drugs Sales (Volume) and Market Share Comparison by Application (2013-2025)
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 EMEA Renal Cell Cacinoma Drugs Market by Region
- 1.4.1 EMEA Renal Cell Cacinoma Drugs Market Size (Value) Comparison by Region (2013-2025)
- 1.4.2 Europe Status and Prospect (2013-2025)
- 1.4.3 Middle East Status and Prospect (2013-2025)
- 1.4.4 Africa Status and Prospect (2013-2025)
- 1.5 EMEA Market Size (Value and Volume) of Renal Cell Cacinoma Drugs (2013-2025)
- 1.5.1 EMEA Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2025)
- 1.5.2 EMEA Renal Cell Cacinoma Drugs Revenue and Growth Rate (2013-2025)
2 EMEA Renal Cell Cacinoma Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
- 2.1 EMEA Renal Cell Cacinoma Drugs Market Competition by Players/Manufacturers
- 2.1.1 EMEA Renal Cell Cacinoma Drugs Sales Volume and Market Share of Major Players (2013-2018)
- 2.1.2 EMEA Renal Cell Cacinoma Drugs Revenue and Share by Players (2013-2018)
- 2.1.3 EMEA Renal Cell Cacinoma Drugs Sale Price by Players (2013-2018)
- 2.2 EMEA Renal Cell Cacinoma Drugs (Volume and Value) by Type/Product Category
- 2.2.1 EMEA Renal Cell Cacinoma Drugs Sales and Market Share by Type (2013-2018)
- 2.2.2 EMEA Renal Cell Cacinoma Drugs Revenue and Market Share by Type (2013-2018)
- 2.2.3 EMEA Renal Cell Cacinoma Drugs Sale Price by Type (2013-2018)
- 2.3 EMEA Renal Cell Cacinoma Drugs (Volume) by Application
- 2.4 EMEA Renal Cell Cacinoma Drugs (Volume and Value) by Region
- 2.4.1 EMEA Renal Cell Cacinoma Drugs Sales and Market Share by Region (2013-2018)
- 2.4.2 EMEA Renal Cell Cacinoma Drugs Revenue and Market Share by Region (2013-2018)
- 2.4.3 EMEA Renal Cell Cacinoma Drugs Sales Price by Region (2013-2018)
3 Europe Renal Cell Cacinoma Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
- 3.1 Europe Renal Cell Cacinoma Drugs Sales and Value (2013-2018)
- 3.1.1 Europe Renal Cell Cacinoma Drugs Sales Volume and Growth Rate (2013-2018)
- 3.1.2 Europe Renal Cell Cacinoma Drugs Revenue and Growth Rate (2013-2018)
- 3.2 Europe Renal Cell Cacinoma Drugs Sales and Market Share by Type
- 3.3 Europe Renal Cell Cacinoma Drugs Sales and Market Share by Application
- 3.4 Europe Renal Cell Cacinoma Drugs Sales Volume and Value (Revenue) by Countries
- 3.4.1 Europe Renal Cell Cacinoma Drugs Sales Volume by Countries (2013-2018)
- 3.4.2 Europe Renal Cell Cacinoma Drugs Revenue by Countries (2013-2018)
- 3.4.3 Germany Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 3.4.4 France Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 3.4.5 UK Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 3.4.6 Russia Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 3.4.7 Italy Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 3.4.8 Benelux Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
4 Middle East Renal Cell Cacinoma Drugs (Volume, Value and Sales Price), by Region, Type and Application
- 4.1 Middle East Renal Cell Cacinoma Drugs Sales and Value (2013-2018)
- 4.1.1 Middle East Renal Cell Cacinoma Drugs Sales Volume and Growth Rate (2013-2018)
- 4.1.2 Middle East Renal Cell Cacinoma Drugs Revenue and Growth Rate (2013-2018)
- 4.2 Middle East Renal Cell Cacinoma Drugs Sales and Market Share by Type
- 4.3 Middle East Renal Cell Cacinoma Drugs Sales and Market Share by Application
- 4.4 Middle East Renal Cell Cacinoma Drugs Sales Volume and Value (Revenue) by Countries
- 4.4.1 Middle East Renal Cell Cacinoma Drugs Sales Volume by Countries (2013-2018)
- 4.4.2 Middle East Renal Cell Cacinoma Drugs Revenue by Countries (2013-2018)
- 4.4.3 Saudi Arabia Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 4.4.4 Israel Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 4.4.5 UAE Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 4.4.6 Iran Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
5 Africa Renal Cell Cacinoma Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
- 5.1 Africa Renal Cell Cacinoma Drugs Sales and Value (2013-2018)
- 5.1.1 Africa Renal Cell Cacinoma Drugs Sales Volume and Growth Rate (2013-2018)
- 5.1.2 Africa Renal Cell Cacinoma Drugs Revenue and Growth Rate (2013-2018)
- 5.2 Africa Renal Cell Cacinoma Drugs Sales and Market Share by Type
- 5.3 Africa Renal Cell Cacinoma Drugs Sales and Market Share by Application
- 5.4 Africa Renal Cell Cacinoma Drugs Sales Volume and Value (Revenue) by Countries
- 5.4.1 Africa Renal Cell Cacinoma Drugs Sales Volume by Countries (2013-2018)
- 5.4.2 Africa Renal Cell Cacinoma Drugs Revenue by Countries (2013-2018)
- 5.4.3 South Africa Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 5.4.4 Nigeria Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 5.4.5 Egypt Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
- 5.4.6 Algeria Renal Cell Cacinoma Drugs Sales and Growth Rate (2013-2018)
6 EMEA Renal Cell Cacinoma Drugs Manufacturers/Players Profiles and Sales Data
- 6.1 Active Biotech Ab
- 6.1.1 Company Basic Information, Manufacturing Base and Competitors
- 6.1.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.1.2.1 Product A
- 6.1.2.2 Product B
- 6.1.3 Active Biotech Ab Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.1.4 Main Business/Business Overview
- 6.2 Amgen
- 6.2.1 Company Basic Information, Manufacturing Base and Competitors
- 6.2.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.2.2.1 Product A
- 6.2.2.2 Product B
- 6.2.3 Amgen Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.2.4 Main Business/Business Overview
- 6.3 Bayer AG
- 6.3.1 Company Basic Information, Manufacturing Base and Competitors
- 6.3.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.3.2.1 Product A
- 6.3.2.2 Product B
- 6.3.3 Bayer AG Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.3.4 Main Business/Business Overview
- 6.4 Cipla Limited
- 6.4.1 Company Basic Information, Manufacturing Base and Competitors
- 6.4.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.4.2.1 Product A
- 6.4.2.2 Product B
- 6.4.3 Cipla Limited Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.4.4 Main Business/Business Overview
- 6.5 F. Hoffmann-La Roche Ag
- 6.5.1 Company Basic Information, Manufacturing Base and Competitors
- 6.5.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.5.2.1 Product A
- 6.5.2.2 Product B
- 6.5.3 F. Hoffmann-La Roche Ag Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.5.4 Main Business/Business Overview
- 6.6 Genentech, Inc.
- 6.6.1 Company Basic Information, Manufacturing Base and Competitors
- 6.6.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.6.2.1 Product A
- 6.6.2.2 Product B
- 6.6.3 Genentech, Inc. Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.6.4 Main Business/Business Overview
- 6.7 Glaxosmithkline Plc
- 6.7.1 Company Basic Information, Manufacturing Base and Competitors
- 6.7.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.7.2.1 Product A
- 6.7.2.2 Product B
- 6.7.3 Glaxosmithkline Plc Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.7.4 Main Business/Business Overview
- 6.8 Novartis Ag
- 6.8.1 Company Basic Information, Manufacturing Base and Competitors
- 6.8.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.8.2.1 Product A
- 6.8.2.2 Product B
- 6.8.3 Novartis Ag Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.8.4 Main Business/Business Overview
- 6.9 Onyx
- 6.9.1 Company Basic Information, Manufacturing Base and Competitors
- 6.9.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.9.2.1 Product A
- 6.9.2.2 Product B
- 6.9.3 Onyx Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.9.4 Main Business/Business Overview
- 6.10 Pfizer, Inc.
- 6.10.1 Company Basic Information, Manufacturing Base and Competitors
- 6.10.2 Renal Cell Cacinoma Drugs Product Type, Application and Specification
- 6.10.2.1 Product A
- 6.10.2.2 Product B
- 6.10.3 Pfizer, Inc. Renal Cell Cacinoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
- 6.10.4 Main Business/Business Overview
7 Renal Cell Cacinoma Drugs Manufacturing Cost Analysis
- 7.1 Renal Cell Cacinoma Drugs Key Raw Materials Analysis
- 7.1.1 Key Raw Materials
- 7.1.2 Price Trend of Key Raw Materials
- 7.1.3 Key Suppliers of Raw Materials
- 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
- 7.2.1 Raw Materials
- 7.2.2 Labor Cost
- 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Renal Cell Cacinoma Drugs
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
- 8.1 Renal Cell Cacinoma Drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Renal Cell Cacinoma Drugs Major Manufacturers in 2017
- 8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
- 9.2.1 Pricing Strategy
- 9.2.2 Brand Strategy
- 9.2.3 Target Client
- 9.3 Distributors/Traders List
10 Market Effect Factors Analysis
- 10.1 Technology Progress/Risk
- 10.1.1 Substitutes Threat
- 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change
11 EMEA Renal Cell Cacinoma Drugs Market Forecast (2018-2025)
- 11.1 EMEA Renal Cell Cacinoma Drugs Sales, Revenue and Price Forecast (2018-2025)
- 11.1.1 EMEA Renal Cell Cacinoma Drugs Sales and Growth Rate Forecast (2018-2025)
- 11.1.2 EMEA Renal Cell Cacinoma Drugs Revenue and Growth Rate Forecast (2018-2025)
- 11.1.3 EMEA Renal Cell Cacinoma Drugs Price and Trend Forecast (2018-2025)
- 11.2 EMEA Renal Cell Cacinoma Drugs Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.3 Europe Renal Cell Cacinoma Drugs Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.4 Middle Eastt Renal Cell Cacinoma Drugs Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.5 Africa Renal Cell Cacinoma Drugs Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
- 11.6 EMEA Renal Cell Cacinoma Drugs Sales Forecast by Type (2018-2025)
- 11.7 EMEA Renal Cell Cacinoma Drugs Sales Forecast by Application (2018-2025)
12 Research Findings and Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
